360 related articles for article (PubMed ID: 25537744)
1. Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.
Ravichandran K; Ozkok A; Wang Q; Mullick AE; Edelstein CL
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F349-57. PubMed ID: 25537744
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade.
Fitzgibbon WR; Dang Y; Bunni MA; Baicu CF; Zile MR; Mullick AE; Saigusa T
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F210-F218. PubMed ID: 29021226
[TBL] [Abstract][Full Text] [Related]
3. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.
Saigusa T; Dang Y; Mullick AE; Yeh ST; Zile MR; Baicu CF; Bell PD
FASEB J; 2016 Jan; 30(1):370-9. PubMed ID: 26391272
[TBL] [Abstract][Full Text] [Related]
4. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
[TBL] [Abstract][Full Text] [Related]
5. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
Loghman-Adham M; Soto CE; Inagami T; Cassis L
Am J Physiol Renal Physiol; 2004 Oct; 287(4):F775-88. PubMed ID: 15187005
[TBL] [Abstract][Full Text] [Related]
6. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
[TBL] [Abstract][Full Text] [Related]
7. Blood Pressure Lowering and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury.
Mullick AE; Yeh ST; Graham MJ; Engelhardt JA; Prakash TP; Crooke RM
Hypertension; 2017 Sep; 70(3):566-576. PubMed ID: 28716988
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
9. Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease.
Wang Q; Cobo-Stark P; Patel V; Somlo S; Han PL; Igarashi P
Kidney Int; 2018 Feb; 93(2):403-415. PubMed ID: 29042084
[TBL] [Abstract][Full Text] [Related]
10. Cyst expansion and regression in a mouse model of polycystic kidney disease.
Happé H; van der Wal AM; Salvatori DC; Leonhard WN; Breuning MH; de Heer E; Peters DJ
Kidney Int; 2013 Jun; 83(6):1099-108. PubMed ID: 23466997
[TBL] [Abstract][Full Text] [Related]
11. Angiotensinogen Exerts Effects Independent of Angiotensin II.
Lu H; Wu C; Howatt DA; Balakrishnan A; Moorleghen JJ; Chen X; Zhao M; Graham MJ; Mullick AE; Crooke RM; Feldman DL; Cassis LA; Vander Kooi CW; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):256-65. PubMed ID: 26681751
[TBL] [Abstract][Full Text] [Related]
12. Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease.
Wang X; Harris PC; Somlo S; Batlle D; Torres VE
Nephrol Dial Transplant; 2009 Feb; 24(2):526-34. PubMed ID: 18826972
[TBL] [Abstract][Full Text] [Related]
13. Hepatic and proximal tubule angiotensinogen play distinct roles in kidney dysfunction, glomerular and tubular injury, and fibrosis progression.
Jang HS; Noh MR; Plumb T; Lee K; He JC; Ferrer FA; Padanilam BJ
Am J Physiol Renal Physiol; 2022 Oct; 323(4):F435-F446. PubMed ID: 35924445
[TBL] [Abstract][Full Text] [Related]
14. Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor-beta1 expression in acute ureteral obstruction.
Shin GT; Kim WH; Yim H; Kim MS; Kim H
Kidney Int; 2005 Mar; 67(3):897-908. PubMed ID: 15698429
[TBL] [Abstract][Full Text] [Related]
15. Angiotensinogen and Megalin Interactions Contribute to Atherosclerosis-Brief Report.
Ye F; Wang Y; Wu C; Howatt DA; Wu CH; Balakrishnan A; Mullick AE; Graham MJ; Danser AHJ; Wang J; Daugherty A; Lu HS
Arterioscler Thromb Vasc Biol; 2019 Feb; 39(2):150-155. PubMed ID: 30567480
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of TGF-β1 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease.
Zhang Y; Dai Y; Raman A; Daniel E; Metcalf J; Reif G; Pierucci-Alves F; Wallace DP
Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1135-F1148. PubMed ID: 33166182
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease.
Seeger-Nukpezah T; Proia DA; Egleston BL; Nikonova AS; Kent T; Cai KQ; Hensley HH; Ying W; Chimmanamada D; Serebriiskii IG; Golemis EA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12786-91. PubMed ID: 23858461
[TBL] [Abstract][Full Text] [Related]
18. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.
Chang MY; Parker E; Ibrahim S; Shortland JR; Nahas ME; Haylor JL; Ong AC
Nephrol Dial Transplant; 2006 Aug; 21(8):2078-84. PubMed ID: 16720597
[TBL] [Abstract][Full Text] [Related]
19. Nonselective Cyclooxygenase Inhibition Retards Cyst Progression in a Murine Model of Autosomal Dominant Polycystic Kidney Disease.
Zhang M; Srichai MB; Zhao M; Chen J; Davis LS; Wu G; Breyer MD; Hao CM
Int J Med Sci; 2019; 16(1):180-188. PubMed ID: 30662341
[No Abstract] [Full Text] [Related]
20. Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease.
Cassini MF; Kakade VR; Kurtz E; Sulkowski P; Glazer P; Torres R; Somlo S; Cantley LG
J Am Soc Nephrol; 2018 Oct; 29(10):2471-2481. PubMed ID: 30209078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
